Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multizentrische prospektive Kohorte mit kardialer Sarkoidose (CHASM-CS)

30. Oktober 2026 aktualisiert von: Ottawa Heart Institute Research Corporation

Kardiale Sarkoidose Multizentrische prospektive Kohortenstudie

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1500

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Sapporo, Japan, 060-8638
        • Rekrutierung
        • Hokkaido University
        • Kontakt:
        • Hauptermittler:
          • Ichizo Tsujino, MD
    • Alberta
      • Calgary, Alberta, Kanada, T2N 2T9
        • Rekrutierung
        • Libin Cardiovascular Institute of Alberta
        • Hauptermittler:
          • Russell Quinn, MD
        • Kontakt:
          • Russell Quinn, MD
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Rekrutierung
        • University of Alberta Hospital
        • Kontakt:
          • Tomascz Hruczkowski, MD
        • Hauptermittler:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Rekrutierung
        • St. Paul's Hospital
        • Kontakt:
          • Shanta Chakrabarti, MD
        • Hauptermittler:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 3A7
        • Rekrutierung
        • QEII Health Sciences Center
        • Hauptermittler:
          • Ciorsti MacIntyre, MD
        • Kontakt:
          • Kim Anderson, MD
    • Ontario
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Rekrutierung
        • Hamilton Health Sciences Centre
        • Hauptermittler:
          • Jeff Healey, MD
        • Kontakt:
          • Gerard Cox, MD
        • Kontakt:
          • Jeff Healey, MD
      • London, Ontario, Kanada, N6A 5A5
        • Rekrutierung
        • London Health Sciences Centre
        • Kontakt:
          • Lorne Gula, MD
        • Hauptermittler:
          • Lorne Gula, MD
      • Newmarket, Ontario, Kanada, L3Y 2P9
        • Rekrutierung
        • Southlake Regional Health Centre
        • Kontakt:
          • Bernice Tsang, MD
        • Hauptermittler:
          • Bernice Tsang, MD
      • Ottawa, Ontario, Kanada, K1Y 4W7
        • Rekrutierung
        • University of Ottawa Heart Institute
        • Kontakt:
        • Hauptermittler:
          • David Birnie, MD
        • Kontakt:
      • Toronto, Ontario, Kanada, M5G 2C4
        • Rekrutierung
        • Toronto General Hospital
        • Kontakt:
          • Andrew Ha, MD
        • Hauptermittler:
          • Andrew Ha, MD
    • Quebec
      • Montreal, Quebec, Kanada, H1T 1C8
        • Rekrutierung
        • Montreal Heart Institute
        • Kontakt:
          • Lena Rivard, MD
        • Hauptermittler:
          • Lena Rivard, MD
      • Montreal, Quebec, Kanada, H3G 1A4
        • Rekrutierung
        • McGill University Health Centre
        • Kontakt:
          • Fiorella Rafti
        • Hauptermittler:
          • Martin L Bernier, MD
      • Montreal, Quebec, Kanada, H2W 1T8
        • Noch keine Rekrutierung
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • Kontakt:
          • Julie Fleury, RN
        • Hauptermittler:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4P 0W5
        • Rekrutierung
        • Prairie Vascular Research Inc-Regina General Hospital
        • Kontakt:
        • Hauptermittler:
          • Andrea Lavoie, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 99 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Electrophysiology Service patients

Beschreibung

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Primary Outcome for ALL Patients
Zeitfenster: Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary Outcomes for ALL Patients
Zeitfenster: Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
Zeitfenster: Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Zeitfenster: Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Zeitfenster: Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
  • Hauptermittler: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
  • Hauptermittler: David Birnie, MD, Ottawa Heart Institute Research Corporation

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. August 2012

Primärer Abschluss (Geschätzt)

1. März 2027

Studienabschluss (Geschätzt)

1. Dezember 2035

Studienanmeldedaten

Zuerst eingereicht

10. November 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. November 2011

Zuerst gepostet (Geschätzt)

22. November 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. Oktober 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • UOHI-04

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .